Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06851065 · ClinicalTrials.gov registry record
A Study to Evaluate Luspatercept Treatment Patterns and Outcomes in Erythropoiesis-Stimulating Agents-Naïve Patients With Lower-Risk Myelodysplastic Syndromes in the United States
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 418
- Enrollment target
NCT06851065: Completed study, sponsored by Bristol-Myers Squibb.
NCT06851065 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 418 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06851065 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 418 participants
- Enrollment target
Study Summary
The purpose of this study is to understand real-world effectiveness of luspatercept treatment among erythropoiesis-stimulating agents -naïve patients with lower-risk- myelodysplastic syndromes in the United States
Interventions
- DRUG Luspatercept
- DRUG Erythropoiesis-stimulating agents
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 418 participants |
| Start Date | 2024-08-22 |
| Est. Completion | 2025-03-10 |
What the finished NCT06851065 record still lists
NCT06851065 is an observational study that tracks outcomes without assigning an intervention. The registered 418 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which Luspatercept is the first listed.
NCT06851065 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06851065 about?
NCT06851065 is a clinical study titled "A Study to Evaluate Luspatercept Treatment Patterns and Outcomes in Erythropoiesis-Stimulating Agents-Naïve Patients With Lower-Risk Myelodysplastic Syndromes in the United States". The purpose of this study is to understand real-world effectiveness of luspatercept treatment among erythropoiesis-stimulating agents -naïve patients with lower-risk- myelodysplastic syndromes in the United States
What is the current status of trial NCT06851065?
This trial is currently completed. The enrollment target is 418 participants. The study started on 2024-08-22. Estimated completion is 2025-03-10.
What interventions are being tested in trial NCT06851065?
The interventions under investigation include: Luspatercept (DRUG), Erythropoiesis-stimulating agents (DRUG).
Who is sponsoring clinical trial NCT06851065?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03135886 · 418 participants · NA
Project I Test: Implementing HIV Testing in Opioid Treatment Programs
- NCT05579639 · 419 participants · Phase 2
Xylitol BSI Multisite - Reduction of Bloodstream Infections From Oral Organisms in Pediatric Stem Cell Transplant
- NCT06169735 · 417 participants · Phase 4
Does Fluorescence With or Without Indocyanine Green Improve Parathyroid Identification and Preservation
- NCT06699901 · 417 participants
Antibiotic Concentrations After MassivE Transfusion Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI